Psychedelic drug development is advancing quickly, but clinical progress often stalls due to small datasets, regulatory uncertainty and a lack of objective biomarkers.
With over 94% of psychiatric compounds failing to reach the market after entering Phase I, this therapeutic area has the second highest attrition rate in drug development. Neuroimaging offers a potential solution by providing a data-driven foundation for more reliable, reproducible and objective advancement across preclinical and clinical stages.
This webinar is designed for researchers, clinical developers and investors looking to accelerate psychedelic therapy programs with scientifically grounded insights. Discover how advanced neuroimaging techniques, such as PET and fMRI, and other multimodal approaches, are clarifying mechanisms of action, validating biomarkers and guiding precision dosing and patient stratification.
Join the featured speaker to explore:
Watch this webinar to see how neuroimaging can optimize psychedelic drug development, reduce risk, improve study design and help bring safe and effective treatments.
Presenters:
Matthew Wall, PhD, Associate Director of Translational MRI, Perceptive Dr. Matthew Wall is a Neuroscientist and Psychologist with expertise in functional MRI and psychopharmacology. He leads translational MRI efforts at Perceptive and holds an honorary academic post at Imperial College London. His research explores how psychedelics like psilocybin and LSD affect brain function, with broader interests in cannabis, sex hormones and fMRI methods. He has held senior imaging roles at Perceptive and Imanova and authored over 90 publications. He is the Editor of the forthcoming book, Pharmacological fMRI: Methods and Applications (2025), which bridges neuroimaging techniques with clinical and drug development applications.
Δ
